Cambridge Investment Research Advisors Inc. Buys New Holdings in Sabra Healthcare REIT, Inc. (SBRA)

Cambridge Investment Research Advisors Inc. bought a new position in shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,843 shares of the real estate investment trust’s stock, valued at approximately $501,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Sabra Healthcare REIT by 9.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,151 shares of the real estate investment trust’s stock worth $100,000 after purchasing an additional 352 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in Sabra Healthcare REIT by 15.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 5,900 shares of the real estate investment trust’s stock valued at $142,000 after purchasing an additional 800 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in Sabra Healthcare REIT by 96.0% during the 2nd quarter. Riverhead Capital Management LLC now owns 6,861 shares of the real estate investment trust’s stock valued at $165,000 after purchasing an additional 3,361 shares during the last quarter. Flinton Capital Management LLC lifted its holdings in Sabra Healthcare REIT by 96.1% during the 2nd quarter. Flinton Capital Management LLC now owns 6,868 shares of the real estate investment trust’s stock valued at $165,000 after purchasing an additional 3,366 shares during the last quarter. Finally, Laurion Capital Management LP bought a new position in shares of Sabra Healthcare REIT in the second quarter worth about $200,000. Institutional investors own 85.51% of the company’s stock.

Sabra Healthcare REIT, Inc. (SBRA) opened at $19.00 on Wednesday. The company has a market cap of $3,443.45, a PE ratio of 8.47, a PEG ratio of 2.51 and a beta of 0.92. Sabra Healthcare REIT, Inc. has a fifty-two week low of $18.48 and a fifty-two week high of $29.10. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.89.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 30th. Investors of record on Wednesday, November 15th were issued a $0.07 dividend. The ex-dividend date was Tuesday, November 14th. This represents a $0.28 dividend on an annualized basis and a yield of 1.47%. Sabra Healthcare REIT’s dividend payout ratio (DPR) is presently 221.28%.

In other Sabra Healthcare REIT news, Director Milton J. Walters sold 4,615 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $19.18, for a total transaction of $88,515.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.60% of the company’s stock.

A number of equities analysts have weighed in on SBRA shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $30.00 target price on shares of Sabra Healthcare REIT in a research note on Friday, September 8th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $22.00 price target on shares of Sabra Healthcare REIT in a research note on Friday, November 3rd. SunTrust Banks reaffirmed a “buy” rating and issued a $30.00 price target on shares of Sabra Healthcare REIT in a research note on Monday, October 9th. Capital One Financial began coverage on shares of Sabra Healthcare REIT in a research report on Monday, September 25th. They issued an “equal weight” rating and a $24.00 price objective on the stock. Finally, TheStreet lowered shares of Sabra Healthcare REIT from a “b-” rating to a “c” rating in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. Sabra Healthcare REIT presently has an average rating of “Hold” and an average price target of $24.40.

ILLEGAL ACTIVITY NOTICE: “Cambridge Investment Research Advisors Inc. Buys New Holdings in Sabra Healthcare REIT, Inc. (SBRA)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/12/06/22843-shares-in-sabra-healthcare-reit-inc-sbra-purchased-by-cambridge-investment-research-advisors-inc.html.

Sabra Healthcare REIT Profile

Sabra Health Care REIT, Inc is a real estate investment trust. The Company, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company’s segment includes investments in healthcare-related real estate properties. The Company’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector.

Institutional Ownership by Quarter for Sabra Healthcare REIT (NASDAQ:SBRA)

Receive News & Ratings for Sabra Healthcare REIT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply